We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

Fund managers haven’t disclosed any holdings of JNCE yet.

JNCE Hedge Fund Activity: Q3 2023 in Review

0 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q3 2023, worth a combined $0 — down 100% from $918K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of JNCE and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Opaleye Management, exiting entirely with an estimated $918K sold.

  • 0 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q3 2023, down from 1 in Q2 2023.
  • Funds reported $0 of Jounce Therapeutics, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q3 2023 and 1 closed out, a net change of -1 holder.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q3 2023 was Opaleye Management, an estimated $918K sold.

Based on aggregated 13F filings for Q3 2023.